REG - N4 Pharma PLC - Posting of Annual Report & Notice of AGM

N4 PharmaAnnouncement

29/04/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240429:nRSc4170Ma&default-theme=true

RNS Number : 4170M  N4 Pharma PLC  29 April 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Posting of Annual Report & Notice of AGM

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that its Annual Report and Accounts for the year ended 31 December 2023 and
Notice of its Annual General Meeting ("AGM") have been posted to shareholders.

 

The AGM will be held at 11:00am on 23 May 2024 at Shakespeare Martineau LLP,
6th Floor 60 Gracechurch Street, London, EC3V 0HR.

 

The Group's Annual Report and Accounts and the Notice of AGM are available on
the Company's website: https://www.n4pharma.com/ (https://www.n4pharma.com/)

 

 

For more information please contact:

 

 N4 Pharma plc                                                        investors.n4pharma.com (http://investors.n4pharma.com)

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 InvestorHub                                                          Sign up at investors.n4pharma.com (http://investors.n4pharma.com)

 Engage with us directly at N4 Pharma Investor Hub

                                                                      https://investors.n4pharma.com/link/4PKgJP
                                                                      (https://investors.n4pharma.com/link/4PKgJP)

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at www.investors.n4pharma.com
(http://www.investors.n4pharma.com) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASEASUUELSEIL